Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
JNJ-6420
i
Other names:
JNJ-6420, 225Ac-DOTA-h11B6, Actinium-225-labeled Anti-kallikrein-2 h11B6, JNJ-69086420
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
J&J
Drug class:
α radiation emission, KLK2 inhibitor
Related drugs:
‹
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
ORM-2110 (1)
BAY2701439 (1)
I-131-apamistamab (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
Iomab-ACT (0)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
212Pb-VMT-𝛼-NET (0)
AAA817 (0)
AB001 (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
[212Pb]VMT01 (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
CONV01-α (0)
BAY 2287411 (0)
JNJ-8343 (0)
Ac-225 ErbB3 targeted radiotherapy (4)
lintuzumab-Ac225 (4)
RYZ101 (2)
ORM-2110 (1)
BAY2701439 (1)
I-131-apamistamab (1)
Undisclosed EGFRvIII-targeted alpha therapy (1)
Iomab-ACT (0)
211At-OKT10-B10 (0)
212Pb-DOTAM-GRPR1 (0)
212Pb-VMT-𝛼-NET (0)
AAA817 (0)
AB001 (0)
FPI-1434 (0)
FPI-1966 (0)
FPI-2265 (0)
[212Pb]VMT01 (0)
[²¹¹At]PTT (0)
BAY 2315497 (0)
CONV01-α (0)
BAY 2287411 (0)
JNJ-8343 (0)
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login